Myovant Sciences Ltd. (NYSE:MYOV) General Counsel Matthew Lang Sells 1,272 Shares

Myovant Sciences Ltd. (NYSE:MYOVGet Rating) General Counsel Matthew Lang sold 1,272 shares of the business’s stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $26.89, for a total value of $34,204.08. Following the completion of the sale, the general counsel now owns 354,303 shares of the company’s stock, valued at $9,527,207.67. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Matthew Lang also recently made the following trade(s):

  • On Wednesday, January 4th, Matthew Lang sold 2,779 shares of Myovant Sciences stock. The shares were sold at an average price of $26.90, for a total value of $74,755.10.

Myovant Sciences Stock Up 0.1 %

Shares of MYOV opened at $26.89 on Monday. Myovant Sciences Ltd. has a 12-month low of $7.67 and a 12-month high of $27.02. The business has a 50-day simple moving average of $26.87 and a two-hundred day simple moving average of $21.93. The stock has a market cap of $2.60 billion, a PE ratio of -13.45 and a beta of 2.20.

Myovant Sciences (NYSE:MYOVGet Rating) last issued its earnings results on Wednesday, October 26th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $104.82 million during the quarter, compared to analyst estimates of $92.00 million. On average, equities research analysts expect that Myovant Sciences Ltd. will post -1.82 EPS for the current year.

Institutional Investors Weigh In On Myovant Sciences

A number of institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System grew its position in shares of Myovant Sciences by 2.6% in the 3rd quarter. California State Teachers Retirement System now owns 36,912 shares of the company’s stock valued at $663,000 after buying an additional 922 shares during the last quarter. Arizona State Retirement System grew its position in shares of Myovant Sciences by 13.5% in the 2nd quarter. Arizona State Retirement System now owns 11,452 shares of the company’s stock valued at $142,000 after buying an additional 1,363 shares during the last quarter. Torray LLC grew its position in shares of Myovant Sciences by 2.2% in the 2nd quarter. Torray LLC now owns 81,621 shares of the company’s stock valued at $1,015,000 after buying an additional 1,753 shares during the last quarter. SeaCrest Wealth Management LLC bought a new stake in shares of Myovant Sciences in the 2nd quarter valued at about $25,000. Finally, Credit Suisse AG grew its position in shares of Myovant Sciences by 9.9% in the 2nd quarter. Credit Suisse AG now owns 28,907 shares of the company’s stock valued at $359,000 after buying an additional 2,593 shares during the last quarter. Institutional investors own 30.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MYOV. StockNews.com began coverage on Myovant Sciences in a research report on Wednesday, October 12th. They set a “hold” rating for the company. SVB Leerink downgraded Myovant Sciences from an “outperform” rating to a “market perform” rating and upped their target price for the company from $23.00 to $27.00 in a research report on Monday, October 24th. Finally, Robert W. Baird downgraded Myovant Sciences from an “outperform” rating to a “neutral” rating and upped their target price for the company from $20.00 to $27.00 in a research report on Monday, October 24th.

About Myovant Sciences

(Get Rating)

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Read More

Insider Buying and Selling by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.